{"id":"W1496015604","doi":"10.1016/s1387-2656(05)11012-6","title":"A Prospective, non-randomised phase 1–2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma","year":2005,"lang":"en","type":"article","venue":"Biotechnology annual review","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Amgen (Canada); Interior Health; Hôpital Maisonneuve-Rosemont; St. Michael's Hospital; Hamilton Health Sciences; Royal Victoria Hospital; University of Toronto; University Health Network; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Filgrastim; Regimen; Etoposide; Internal medicine; Gastroenterology; Leukocytopenia; Chemotherapy; Vincristine; Surgery; Neutropenia; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002769429,0.001787948,0.00384645,0.0005015054,0.0006809375,0.001587982,0.00137951,0.002229472,0.007749881],"category_scores_gemma":[0.002166278,0.0007442098,0.002353984,0.0006327936,0.002165033,0.001965828,0.0006591637,0.005051068,0.001571388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001138613,"about_ca_system_score_gemma":0.001317018,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001630073,"about_ca_topic_score_gemma":0.002270353,"domain_scores_codex":[0.9986779,0.0007497837,0.00006087829,0.0001929928,0.00007548357,0.0002429507],"domain_scores_gemma":[0.9985042,0.0004979058,0.0001953584,0.0001759892,0.00007677452,0.000549885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9812836,0.004487875,0.0003846554,0.0002541649,0.0005259512,0.00003047552,0.00004695138,0.0002676859,0.001520967,0.0001148173,0.0004890128,0.01059383],"study_design_scores_gemma":[0.9272173,0.0704513,0.001013756,0.0000175664,0.0002177968,0.00002371665,0.00002267846,0.0001500662,0.0001882667,0.0001666988,0.0005208665,0.00001007427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816152,0.007805174,0.0009921215,0.001298458,0.001141066,0.00338489,0.001218078,0.0000931504,0.002451848],"genre_scores_gemma":[0.9824023,0.003529831,0.001917892,0.002011833,0.0006596533,0.003628543,0.001865446,0.00004202433,0.003942538],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007749881,"threshold_uncertainty_score":0.02592593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007921199552399005,"score_gpt":0.2994663680224409,"score_spread":0.2915451684700419,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}